Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SP-563
- Development stage
- Preclinical
- Lead developer
- Stamford Pharmaceuticals
01
Overview
SP-563 is an investigational vector-drug conjugate (VDC) currently in preclinical development by Stamford Pharmaceuticals for the treatment of non-muscle invasive bladder cancer (NMIBC). Developed as part of the company's proprietary VDC platform, SP-563 is designed to utilize a vector-based delivery mechanism to transport a therapeutic payload directly to malignant cells within the bladder. While specific details regarding the molecular target and the nature of the conjugated payload have not been publicly disclosed, the VDC approach aims to enhance therapeutic efficacy while minimizing systemic exposure and associated side effects. The program represents a targeted expansion of Stamford Pharmaceuticals' pipeline into urological oncology.
02
Targets
IFNGR1 (Interferon gamma receptor 1)
Beyond the preview
Go deeper on SP-563.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SP-563.